Abstract
Chronic tissue and organ failure caused by an injury, disease, ageing or congenital defects represents some of the most complex therapeutic challenges and poses a significant financial healthcare burden. Regenerative medicine strategies aim to fulfil the unmet clinical need by restoring the normal tissue function either through stimulating the endogenous tissue repair or by using transplantation strategies to replace the missing or defective cells. Stem cells represent an essential pillar of regenerative medicine efforts as they provide a source of progenitors or differentiated cells for use in cell replacement therapies. Whilst significant leaps have been made in controlling the stem cell fates and differentiating them to cell types of interest, transitioning bespoke cellular products from an academic environment to off-the-shelf clinical treatments brings about a whole new set of challenges which encompass manufacturing, regulatory and funding issues. Notwithstanding the need to resolve such issues before cell replacement therapies can benefit global healthcare, mounting progress in the field has highlighted regenerative medicine as a realistic prospect for treating some of the previously incurable conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mason C, Dunnill P (2008) A brief definition of regenerative medicine. Regen Med 3:1–5. doi:10.2217/17460751.3.1.1
Nikolich-Zugich J et al (2016) Preparing for an aging world: engaging biogerontologists, geriatricians, and the society. J Gerontol A Biol Sci Med Sci 71:435–444. doi:10.1093/gerona/glv164
Burt RK et al (2008) Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 299:925–936. doi:10.1001/jama.299.8.925
Moore KA, Lemischka IR (2006) Stem cells and their niches. Science 311:1880–1885. doi:10.1126/science.1110542
Evans MJ, Kaufman MH (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154–156
Martin GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 78:7634–7638
Thomson JA et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147
Till JE, Mc CE (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213–222
Becker AJ, Mc CE, Till JE (1963) Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197:452–454
Thomas ED (1999) A history of haemopoietic cell transplantation. Br J Haematol 105:330–339
Osawa M, Hanada K, Hamada H, Nakauchi H (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242–245
Majeti R, Park CY, Weissman IL (2007) Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1:635–645. doi:10.1016/j.stem.2007.10.001
Barker N, van de Wetering M, Clevers H (2008) The intestinal stem cell. Genes Dev 22:1856–1864. doi:10.1101/gad.1674008
Potten CS, Kovacs L, Hamilton E (1974) Continuous labelling studies on mouse skin and intestine. Cell Tissue Kinet 7:271–283
Barker N, Clevers H (2007) Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 133:1755–1760. doi:10.1053/j.gastro.2007.10.029
Sato T et al (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:262–265. doi:10.1038/nature07935
Eriksson PS et al (1998) Neurogenesis in the adult human hippocampus. Nat Med 4:1313–1317. doi:10.1038/3305
Lois C, Alvarez-Buylla A (1993) Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci U S A 90:2074–2077
Casarosa S, Bozzi Y, Conti L (2014) Neural stem cells: ready for therapeutic applications? Mol Cell Ther 2:31. doi:10.1186/2052-8426-2-31
Tabar V, Studer L (2014) Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet 15:82–92. doi:10.1038/nrg3563
Takahashi K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. doi:10.1016/j.cell.2007.11.019
International Stem Cell, I et al (2007) Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25:803–816. doi:10.1038/nbt1318
Hentze H et al (2009) Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res 2:198–210. doi:10.1016/j.scr.2009.02.002
Damjanov I, Andrews PW (2016) Teratomas produced from human pluripotent stem cells xenografted into immunodeficient mice – a histopathology atlas. Int J Dev Biol 60:337–419. doi:10.1387/ijdb.160274id
Murry CE, Keller G (2008) Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132:661–680. doi:10.1016/j.cell.2008.02.008
Osafune K et al (2008) Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol 26:313–315. doi:10.1038/nbt1383
Wichterle H, Lieberam I, Porter JA, Jessell TM (2002) Directed differentiation of embryonic stem cells into motor neurons. Cell 110:385–397
Williams LA, Davis-Dusenbery BN, Eggan KC (2012) SnapShot: directed differentiation of pluripotent stem cells. Cell 149:1174–1174 e1171. doi:10.1016/j.cell.2012.05.015
Trounson A, DeWitt ND (2016) Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 17:194–200. doi:10.1038/nrm.2016.10
Varma AK et al (2013) Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers. Neurochem Res 38:895–905. doi:10.1007/s11064-013-0991-6
Irvine KA, Blakemore WF (2008) Remyelination protects axons from demyelination-associated axon degeneration. Brain 131:1464–1477. doi:10.1093/brain/awn080
Faulkner J, Keirstead HS (2005) Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl Immunol 15:131–142. doi:10.1016/j.trim.2005.09.007
Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS (2005) Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49:385–396. doi:10.1002/glia.20127
Yasuda A et al (2011) Significance of remyelination by neural stem/progenitor cells transplanted into the injured spinal cord. Stem Cells 29:1983–1994. doi:10.1002/stem.767
All AH et al (2015) Early intervention for spinal cord injury with human induced pluripotent stem cells oligodendrocyte progenitors. PLoS One 10:e0116933. doi:10.1371/journal.pone.0116933
Lebkowski J (2011) GRNOPC1: the world’s first embryonic stem cell-derived therapy. Interview with Jane Lebkowski. Regen Med 6:11–13. doi:10.2217/rme.11.77
Baker M (2011) Stem-cell pioneer bows out. Nature 479:459. doi:10.1038/479459a
de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5:525–535. doi:10.1016/S1474-4422(06)70471-9
Hely MA et al (1999) The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67:300–307
Barker RA, Drouin-Ouellet J, Parmar M (2015) Cell-based therapies for Parkinson disease-past insights and future potential. Nat Rev Neurol 11:492–503. doi:10.1038/nrneurol.2015.123
Kefalopoulou Z et al (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71:83–87. doi:10.1001/jamaneurol.2013.4749
Kriks S et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551. doi:10.1038/nature10648
Grealish S et al (2014) Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease. Cell Stem Cell 15:653–665. doi:10.1016/j.stem.2014.09.017
Barker RA, Studer L, Cattaneo E, Takahashi J (2015) G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease. Npj Parkinson’s Disease 1:15017. doi:10.1038/npjparkd.2015.17
Li W et al (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A 113:6544–6549. doi:10.1073/pnas.1605245113
Morizane A, Takahashi J (2016) Cell therapy for Parkinson’s disease. Neurol Med Chir (Tokyo) 56:102–109. doi:10.2176/nmc.ra.2015-0303
Scudellari M (2016) How iPS cells changed the world. Nature 534:310–312. doi:10.1038/534310a
Barker RA et al (2016) Are stem cell-based therapies for Parkinson’s disease ready for the clinic in 2016? J Parkinsons Dis 6:57–63. doi:10.3233/JPD-160798
McKeown SJ, Stamp L, Hao MM, Young HM (2013) Hirschsprung disease: a developmental disorder of the enteric nervous system. Wiley Interdiscip Rev Dev Biol 2:113–129. doi:10.1002/wdev.57
Sasselli V, Pachnis V, Burns AJ (2012) The enteric nervous system. Dev Biol 366:64–73. doi:10.1016/j.ydbio.2012.01.012
Lake JI, Heuckeroth RO (2013) Enteric nervous system development: migration, differentiation, and disease. Am J Physiol Gastrointest Liver Physiol 305:G1–24. doi:10.1152/ajpgi.00452.2012
Burns AJ et al (2016) White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies. Dev Biol 417:229–251. doi:10.1016/j.ydbio.2016.04.001
Burns AJ, Thapar N (2014) Neural stem cell therapies for enteric nervous system disorders. Nat Rev Gastroenterol Hepatol 11:317–328. doi:10.1038/nrgastro.2013.226
Bondurand N, Natarajan D, Thapar N, Atkins C, Pachnis V (2003) Neuron and glia generating progenitors of the mammalian enteric nervous system isolated from foetal and postnatal gut cultures. Development 130:6387–6400. doi:10.1242/dev.00857
Cooper JE et al (2016) In vivo transplantation of enteric neural crest cells into mouse gut; engraftment, functional integration and long-term safety. PLoS One 11:e0147989. doi:10.1371/journal.pone.0147989
Fattahi F et al (2016) Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung disease. Nature 531:105–109. doi:10.1038/nature16951
Workman MJ et al (2017) Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med 23:49–59. doi:10.1038/nm.4233
Xu B et al (2013) Non-linear elasticity of core/shell spun PGS/PLLA fibres and their effect on cell proliferation. Biomaterials 34:6306–6317. doi:10.1016/j.biomaterials.2013.05.009
Burridge PW et al (2014) Chemically defined generation of human cardiomyocytes. Nat Methods 11:855–860. doi:10.1038/nmeth.2999
Lippmann ES, Estevez-Silva MC, Ashton RS (2014) Defined human pluripotent stem cell culture enables highly efficient neuroepithelium derivation without small molecule inhibitors. Stem Cells 32:1032–1042. doi:10.1002/stem.1622
Bao X, Lian X, Palecek SP (2016) Directed endothelial progenitor differentiation from human pluripotent stem cells via Wnt activation under defined conditions. Methods Mol Biol 1481:183–196. doi:10.1007/978-1-4939-6393-5_17
Cheung C, Bernardo AS, Trotter MW, Pedersen RA, Sinha S (2012) Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat Biotechnol 30:165–173. doi:10.1038/nbt.2107
Jonsson MK et al (2012) Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. J Mol Cell Cardiol 52:998–1008. doi:10.1016/j.yjmcc.2012.02.002
van den Berg CW et al (2015) Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells. Development 142:3231–3238. doi:10.1242/dev.123810
Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR (2015) Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 61:1370–1381. doi:10.1002/hep.27621
Hrvatin S et al (2014) Differentiated human stem cells resemble fetal, not adult, beta cells. Proc Natl Acad Sci U S A 111:3038–3043. doi:10.1073/pnas.1400709111
Cornacchia D, Studer L (2017) Back and forth in time: directing age in iPSC-derived lineages. Brain Res 1656:14–26. doi:10.1016/j.brainres.2015.11.013
Wu H et al (2007) Integrative genomic and functional analyses reveal neuronal subtype differentiation bias in human embryonic stem cell lines. Proc Natl Acad Sci U S A 104:13821–13826. doi:10.1073/pnas.0706199104
Nishizawa M et al (2016) Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity. Cell Stem Cell 19:341–354. doi:10.1016/j.stem.2016.06.019
Gu E, Chen WY, Gu J, Burridge P, Wu JC (2012) Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics 2:335–345. doi:10.7150/thno.3666
van Laake LW, Passier R, Doevendans PA, Mummery CL (2008) Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res 102:1008–1010. doi:10.1161/CIRCRESAHA.108.175505
Zhang YW, Denham J, Thies RS (2006) Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. Stem Cells Dev 15:943–952. doi:10.1089/scd.2006.15.943
Lui KO et al (2014) Tolerance induction to human stem cell transplants with extension to their differentiated progeny. Nat Commun 5:5629. doi:10.1038/ncomms6629
Figueiredo C, Blasczyk R (2015) A future with less HLA: potential clinical applications of HLA-universal cells. Tissue Antigens 85:443–449. doi:10.1111/tan.12564
Goldring CE et al (2011) Assessing the safety of stem cell therapeutics. Cell Stem Cell 8:618–628. doi:10.1016/j.stem.2011.05.012
Draper JS et al (2004) Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 22:53–54. doi:10.1038/nbt922
Baker D et al (2016) Detecting genetic mosaicism in cultures of human pluripotent stem cells. Stem Cell Rep 7:998–1012. doi:10.1016/j.stemcr.2016.10.003
Garber K (2015) RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol 33:890–891. doi:10.1038/nbt0915-890
Chakradhar S (2016) An eye to the future: researchers debate best path for stem cell-derived therapies. Nat Med 22:116–119. doi:10.1038/nm0216-116
Cyranoski D (2014) Japanese woman is first recipient of next-generation stem cells. Nature. doi:10.1038/nature.2014.15915
Acknowledgements
We would like to thank Dr Paul J. Gokhale for critical reading of the manuscript. NFB and IB are supported by the UK Regenerative Medicine Platform (grant number MR/L012537/1). IB is also funded by the Medical Research Council (grant number MR/N009371/1) and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668724.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Blair, N.F., Frith, T.J.R., Barbaric, I. (2017). Regenerative Medicine: Advances from Developmental to Degenerative Diseases. In: El-Khamisy, S. (eds) Personalised Medicine. Advances in Experimental Medicine and Biology, vol 1007. Springer, Cham. https://doi.org/10.1007/978-3-319-60733-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-60733-7_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-60731-3
Online ISBN: 978-3-319-60733-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)